We are live on ! Find out more
CMMB icon

Chemomab Therapeutics
CMMB

17 hedge funds and large institutions have $1.44M invested in Chemomab Therapeutics in 2023 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

2,983% more capital inflows, than outflows

Capital inflows: $188K | Capital outflows: $6.1K

250% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 2

42% more funds holding

Funds holding: 12 → 17 (+5)

3.54% more ownership

Funds ownership: 21.5% → 25.04% (+3.5%)

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

Holders
17
Holders Change
+5
Holders Change %
+41.67%
% of All Funds
0.25%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
1
Reduced
2
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$46.7K
2
Two Sigma Investments
Two Sigma Investments
New York
+$37.1K
3
Two Sigma Advisers
Two Sigma Advisers
New York
+$23.3K
4
Citadel Advisors
Citadel Advisors
Florida
+$21.5K
5
XTX Topco
XTX Topco
Cayman Islands
+$19.1K

Top Sellers

Rank Fund Capital Flow
1
Advisory Services Network
Advisory Services Network
Georgia
-$4.2K
2
Newbridge Financial Services Group
Newbridge Financial Services Group
Florida
-$985
3
Osaic Holdings
Osaic Holdings
Arizona
-$785
4
UBS Group
UBS Group
Switzerland
-$126

CMMB Hedge Fund Activity: Q4 2023 in Review

17 of the 6,876 institutional investors tracked by Wall St. Rank reported a position in Chemomab Therapeutics (CMMB) for Q4 2023, worth a combined $1.44M — down 37% from $2.27M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new CMMB positions and 2 closed out — a net gain of 5 holders — while 1 added to existing stakes and 2 trimmed.

The largest buyer was Morgan Stanley, opening a new position worth an estimated $46.7K. The largest seller was Advisory Services Network, cutting an estimated $4.2K.

  • 17 institutional investors held Chemomab Therapeutics (CMMB) as of Q4 2023, up from 12 in Q3 2023.
  • Funds reported $1.44M of Chemomab Therapeutics stock for Q4 2023, down 37% quarter-over-quarter.
  • 7 funds opened new Chemomab Therapeutics positions in Q4 2023 and 2 closed out, a net change of +5 holders.
  • The largest Chemomab Therapeutics buyer in Q4 2023 was Morgan Stanley, an estimated $46.7K added.
  • The largest Chemomab Therapeutics seller in Q4 2023 was Advisory Services Network, an estimated $4.2K sold.

Based on aggregated 13F filings for Q4 2023.